Search Results - "Hardaker, Elizabeth L"

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery by Taylor, Molly A., Hughes, Adina M., Walton, Josephine, Coenen-Stass, Anna M. L., Magiera, Lukasz, Mooney, Lorraine, Bell, Sigourney, Staniszewska, Anna D., Sandin, Linda C., Barry, Simon T., Watkins, Amanda, Carnevalli, Larissa S., Hardaker, Elizabeth L.

“…BackgroundThe ability to modulate immune-inhibitory pathways using checkpoint blockade antibodies such as αPD-1, αPD-L1, and αCTLA-4 represents a significant…”
Get full text

Functional significance of co-occurring mutations in PIK3CA and MAP3K1 in breast cancer by Avivar-Valderas, Alvaro, McEwen, Robert, Taheri-Ghahfarokhi, Amir, Carnevalli, Larissa S, Hardaker, Elizabeth L, Maresca, Marcello, Hudson, Kevin, Harrington, Elizabeth A, Cruzalegui, Francisco

“…The PI3Kα signaling pathway is frequently hyper-activated in breast cancer (BrCa), as a result of mutations/amplifications in oncogenes (e.g. ), decreased…”
Get full text

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment by Hardaker, Elizabeth L., Sanseviero, Emilio, Karmokar, Ankur, Taylor, Devon, Milo, Marta, Michaloglou, Chrysis, Hughes, Adina, Mai, Mimi, King, Matthew, Solanki, Anisha, Magiera, Lukasz, Miragaia, Ricardo, Kar, Gozde, Standifer, Nathan, Surace, Michael, Gill, Shaan, Peter, Alison, Talbot, Sara, Tohumeken, Sehmus, Fryer, Henderson, Mostafa, Ali, Mulgrew, Kathy, Lam, Carolyn, Hoffmann, Scott, Sutton, Daniel, Carnevalli, Larissa, Calero-Nieto, Fernando J., Jones, Gemma N., Pierce, Andrew J., Wilson, Zena, Campbell, David, Nyoni, Lynet, Martins, Carla P., Baker, Tamara, Serrano de Almeida, Gilberto, Ramlaoui, Zainab, Bidar, Abdel, Phillips, Benjamin, Boland, Joseph, Iyer, Sonia, Barrett, J. Carl, Loembé, Arsene-Bienvenu, Fuchs, Serge Y., Duvvuri, Umamaheswar, Lou, Pei-Jen, Nance, Melonie A., Gomez Roca, Carlos Alberto, Cadogan, Elaine, Critichlow, Susan E., Fawell, Steven, Cobbold, Mark, Dean, Emma, Valge-Archer, Viia, Lau, Alan, Gabrilovich, Dmitry I., Barry, Simon T.

“…The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical…”
Get full text

Second-generation inhibitors demonstrate the involvement of p38 mitogen-activated protein kinase in post-transcriptional modulation of inflammatory mediator production in human and rodent airways by Birrell, Mark A, Wong, Sissie, McCluskie, Kerryn, Catley, Matthew C, Hardaker, Elizabeth L, Haj-Yahia, Saleem, Belvisi, Maria G

“…The exact role of p38 mitogen-activated protein kinase (MAPK) in the expression of inflammatory cytokines is not clear; it may regulate transcriptionally,…”
Get more information

Estrogen receptor beta: expression profile and possible anti-inflammatory role in disease by Catley, Matthew C, Birrell, Mark A, Hardaker, Elizabeth L, de Alba, Jorge, Farrow, Stuart, Haj-Yahia, Saleem, Belvisi, Maria G

“…Estrogen receptor (ER) beta agonists have been demonstrated to possess anti-inflammatory properties in inflammatory disease models. The objective of this study…”
Get more information

Regulation of TNF‐α and IFN‐γ induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease by Hardaker, Elizabeth L., Bacon, Alicia M., Carlson, Karey, Roshak, Amy K., Foley, James J., Schmidt, Dulcie B., Buckley, Peter T., Comegys, Meghan, Panettieri, Reynold A., Sarau, Henry M., Belmonte, Kristen E.

“…ABSTRACT The chemokine CXCL10 is produced by many inflammatory cells found in the diseased lung and has been implicated in the pathogenesis of chronic…”
Get full text

IkappaB kinase-2-independent and -dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic by Birrell, Mark A, Wong, Sissie, Hardaker, Elizabeth L, Catley, Matthew C, McCluskie, Kerryn, Collins, Michael, Haj-Yahia, Saleem, Belvisi, Maria G

“…Nuclear factor kappaB (NF-kappaB) is a transcription factor believed to be central in the expression of numerous inflammatory genes and the pathogenesis of…”
Get more information